Latest News

Bulevirtide Monotherapy Well-Tolerated, Safe for Chronic Hepatitis Delta at Week 48
Bulevirtide Monotherapy Well-Tolerated, Safe for Chronic Hepatitis Delta at Week 48

December 11th 2024

In this study, investigators described the safety and tolerability of BLV therapy following 48 weeks of therapy among those with CHD.

Credit: Pexels/ SHVETS production
Novel Model Performs Well in Identifying Liver Fibrosis Risk in Patients with Diabetes

December 11th 2024

COVID-19 Vaccine | Credit: Pexels
COVID-19 Vaccine Efficacy Reduced With Immunosuppressive, Antiviral HBV Drug Use

December 11th 2024

Study Highlights Traits of Patients with Alcohol-Associated Cirrhosis Seeking Treatment
Study Highlights Traits of Patients with Alcohol-Associated Cirrhosis Seeking Treatment

December 11th 2024

Taotao Yan, MD, PhD I Stanford Medicine
Study Finds Sex Differences in MASLD Adverse Events: Cirrhosis Greater Risk in Women

December 11th 2024

Video Interviews
Podcasts
Autoimmune Hepatitis at ACG 2023, with Gina Choi, MD

More News

© 2024 MJH Life Sciences

All rights reserved.